Aim: To assess and report the efficacy of and tolerance to bevacizumab-based chemotherapy in treatment outcome of metastatic poorly differentiated neuroendocrine tumors.
Patients And Methods: From 2007 to 2018, 11 consecutive patients with metastatic poorly differentiated neuroendocrine treated in first- or second-line with bevacizumab-based chemotherapies were included in this monocentric retrospective cohort. Tumor response was evaluated by computed tomographic scans.
Results: Administered treatment included 5-fluorouracil and irinotecan (FOLFIRI) bevacizumab, 5-fluorouracil and oxaliplatin (FOLFOX) bevacizumab and 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRINOX) bevacizumab for four, two and five patients, respectively. Three were treated in first-line and eight in second-line after cisplatin-etoposide regimen. Using Response Evaluation Criteria in Solid Tumors, partial response was observed for seven patients, and stable disease for one patient, giving a response rate of 63.6% (95% confidence interval=35.2-92.1%) and disease control rate of 72.7% (95% confidence interval=46.6-99.0%). All patients had died by the time of analysis, median progression-free survival was 14 months, and median overall survival was 15.3 months. Observed toxicity with such protocols was classical with 10 grade 3-4 toxic events, including three of hematological toxicity, three of infection, and three of digestive toxicity.
Conclusion: Bevacizumab-based chemotherapy gave surprising efficacy and safety in first-or second-line treatment for metastatic poorly differentiated neuroendocrine tumor in this retrospective cohort. Prospective randomized trials of such therapy are warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.12943 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Addition of Bevacizumab to Chemotherapy and Its Impact on Clinical Efficacy in Cervical Cancer: A Systematic Review and Meta-Analysis.
Pharmacy (Basel)
December 2024
Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, George Town 11800, Penang, Malaysia.
: Cervical cancer is the third leading cause of cancer-related mortality in females. One of the most successful therapeutic modalities to date is suppressing vascular endothelial growth factor (VEGF)-mediated angiogenesis. Bevacizumab is a monoclonal antibody that targets VEGF-A.
View Article and Find Full Text PDFImproving the prediction of patient survival with the aid of residual convolutional neural network (ResNet) in colorectal cancer with unresectable liver metastases treated with bevacizumab-based chemotherapy.
Cancer Imaging
December 2024
Division of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Background: To verify overall survival predictions made with residual convolutional neural network-determined morphological response (ResNet-MR) in patients with unresectable synchronous liver-only metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy (BBC).
Methods: A retrospective review of liver-only mCRC patients treated with BBC from December 2011 to Apr 2021 was performed. Patients who had metachronous liver metastases or received locoregional treatment before the initiation of BBC were excluded.
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses.
Oncologist
December 2024
Department of Medical, Surgical and Health Sciences, University of Trieste, 34147 Trieste, Italy.
Background: Glioblastoma is a highly aggressive primary central nervous system tumor characterized by poor outcomes. In case of relapse or progression to adjuvant chemotherapy, there is no univocal preferred regimen for relapsing glioblastoma.
Methods: We conducted a systematic review and Bayesian trial-level network meta-analyses (NMA) to identify the regimens associated with the best outcomes.
Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy.
Oncologist
October 2024
Medical Oncology Unit, AST1, 61121 Pesaro, Italy.
Background: Clinical and experimental studies indicate that the tumor protein p53 (TP53) gene loss of function due to missense mutations (MMs) may confer sensitivity to anti-angiogenics. This effect seems to be linked to cross-talk mechanisms among TP53, vascular endothelial growth factor (VEGF), and VEGF receptors. We investigated whether specific TP53 MMs are associated with clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy plus Bevacizumab.
View Article and Find Full Text PDFAfatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.
Lung Cancer
November 2024
Department of Genome Biology, Kindai University, Faculty of Medicine, Japan.
Article Synopsis
- The study investigates the combined efficacy of afatinib, an EGFR-tyrosine kinase inhibitor, and bevacizumab, a VEGF inhibitor, in patients with EGFR-mutant non-small cell lung cancer who have become resistant to osimertinib.
- Out of 28 enrolled patients, the combination treatment resulted in a 17.9% response rate and an overall disease control rate of 78.6%, with a median duration of response of 9 months.
- The analysis of rebiopsied samples identified various resistance mechanisms, revealing that certain mutations (like C797S and uncommon EGFR mutations) were associated with better responses, while patients with T790M
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!